These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28195393)

  • 21. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
    Green RC; Parfrey PS; Woods MO; Younghusband HB
    J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of germline variants with pathogenic potential in 48 patients with familial colorectal cancer by using whole exome sequencing.
    Singh AK; Talseth-Palmer B; Xavier A; Scott RJ; Drabløs F; Sjursen W
    BMC Med Genomics; 2023 Jun; 16(1):126. PubMed ID: 37296477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer.
    Esteban-Jurado C; Vila-Casadesús M; Garre P; Lozano JJ; Pristoupilova A; Beltran S; Muñoz J; Ocaña T; Balaguer F; López-Cerón M; Cuatrecasas M; Franch-Expósito S; Piqué JM; Castells A; Carracedo A; Ruiz-Ponte C; Abulí A; Bessa X; Andreu M; Bujanda L; Caldés T; Castellví-Bel S
    Genet Med; 2015 Feb; 17(2):131-42. PubMed ID: 25058500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of rare germline copy number variations and common susceptibility loci in Lynch syndrome patients negative for mutations in the mismatch repair genes.
    Villacis RA; Miranda PM; Gomy I; Santos EM; Carraro DM; Achatz MI; Rossi BM; Rogatto SR
    Int J Cancer; 2016 Apr; 138(8):1928-35. PubMed ID: 26620301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
    Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
    Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.
    Ponti G; Castellsagué E; Ruini C; Percesepe A; Tomasi A
    Clin Genet; 2015 Jun; 87(6):507-16. PubMed ID: 25345868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.
    Casey G; Lindor NM; Papadopoulos N; Thibodeau SN; Moskow J; Steelman S; Buzin CH; Sommer SS; Collins CE; Butz M; Aronson M; Gallinger S; Barker MA; Young JP; Jass JR; Hopper JL; Diep A; Bapat B; Salem M; Seminara D; Haile R;
    JAMA; 2005 Feb; 293(7):799-809. PubMed ID: 15713769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lynch syndrome and MYH-associated polyposis: review and testing strategy.
    Goodenberger M; Lindor NM
    J Clin Gastroenterol; 2011 Jul; 45(6):488-500. PubMed ID: 21325953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.
    Lage PA; Albuquerque C; Sousa RG; Cravo ML; Salazar M; Francisco I; Maia L; Claro I; Suspiro A; Rodrigues P; Raposo H; Fidalgo PA; Nobre-Leitão C
    Cancer; 2004 Jul; 101(1):172-7. PubMed ID: 15222003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center.
    Poliani L; Greco L; Barile M; Dal Buono A; Bianchi P; Basso G; Giatti V; Genuardi M; Malesci A; Laghi L;
    ESMO Open; 2022 Dec; 7(6):100607. PubMed ID: 36356413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer.
    Seagle HM; Keller SR; Tavtigian SV; Horton C; Holowatyj AN
    J Clin Oncol; 2023 Sep; 41(26):4279-4289. PubMed ID: 37319387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer.
    Liu T; Yan H; Kuismanen S; Percesepe A; Bisgaard ML; Pedroni M; Benatti P; Kinzler KW; Vogelstein B; Ponz de Leon M; Peltomäki P; Lindblom A
    Cancer Res; 2001 Nov; 61(21):7798-802. PubMed ID: 11691795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing.
    Chang PY; Chen JS; Chang NC; Chang SC; Wang MC; Tsai SH; Wen YH; Tsai WS; Chan EC; Lu JJ
    Oncotarget; 2016 Jun; 7(25):37566-37580. PubMed ID: 27121310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome.
    Manders P; Spruijt L; Kets CM; Willems HW; Bodmer D; Hebeda KM; Nagtegaal ID; van Krieken JH; Ligtenberg MJ; Hoogerbrugge N
    Eur J Cancer; 2011 Jun; 47(9):1407-13. PubMed ID: 21273057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch repair protein immunohistochemistry: a useful population screening strategy for Lynch syndrome.
    Musulén E; Sanz C; Muñoz-Mármol AM; Ariza A
    Hum Pathol; 2014 Jul; 45(7):1388-96. PubMed ID: 24768606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.